Tuberculosis in the cytokine era: What rheumatologists need to know

This publication has 11 references indexed in Scilit:

• Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active‐surveillance report
  Arthritis & Rheumatism, 2003
• American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America
  American Journal of Respiratory and Critical Care Medicine, 2003
• TNF Regulates Chemokine Induction Essential for Cell Recruitment, Granuloma Formation, and Clearance of Mycobacterial Infection
  The Journal of Immunology, 2002
• Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
  New England Journal of Medicine, 2001
• Rifampin and Pyrazinamide vs Isoniazid for Prevention of Tuberculosis in HIV-Infected PersonsAn International Randomized Trial
  JAMA, 2000
• Severe Mycobacterial and Salmonella Infections in Interleukin-12 Receptor-Deficient Patients
  Science, 1998
• Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis
  Archives of Disease in Childhood, 1998
• Interferon-γ –Receptor Deficiency in an Infant with Fatal Bacille Calmette–Guérin Infection
  New England Journal of Medicine, 1996
• Tumor necrosis factor-α is required in the protective immune response against mycobacterium tuberculosis in mice
  Immunity, 1995
• A Double-blind Placebo-controlled Clinical Trial of Three Antituberculosis Chemoprophylaxis Regimens in Patients with Silicosis in Hong Kong
  American Review of Respiratory Disease, 1992